<DOC>
	<DOC>NCT00275379</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, placebo-controlled, parallel-design, exploratory study of orally administered ERB-041 in subjects with active IC. The primary objectives of this study will be to investigate ERB-041’s activity on levels of urinary APF, explore the gene expression response in peripheral blood mononuclear cells (PBMC), and to evaluate the safety of ERB-041 in women with active IC.</brief_summary>
	<brief_title>Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis</brief_title>
	<detailed_description />
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis, Interstitial</mesh_term>
	<criteria>Subjects seeking medical treatment for symptoms consistent with IC that have been ongoing for &gt; 9 months or seeking medical treatment for a previous documented diagnosis of IC Subjects who are not surgically sterile or postmenopausal (amenorrheic &gt; 12 months) must agree and commit to the use of a medically acceptable, highly–effective (i.e. doublebarrier or IUD), nonhormonal form of birth control during the study and for 30 days after the last dose of test Use of herbal supplements (except for a daily multivitamin/mineral supplement not containing herbal components) History of cancer (other than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer) with less than 5 years documentation of a diseasefree state Vaginitis or vaginal infection within 1 month before randomization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Cystitis</keyword>
</DOC>